News | October 26, 2022
Novartis maintains growth momentum; Confirms FY’22 Group guidance
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
He also highlighted the need for community awareness for continued implementation of the Covid Appropriate Behaviour (CAB) especially in view of the upcoming festival season
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
The Bulk Drug Park is expected to attract investment of around Rs. 10,000 crore and provide employment to more than 20,000 people
Subscribe To Our Newsletter & Stay Updated
